5 completed, 2 withdrawn, 1 terminated. 3 Phase 2, 3 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Withdrawn 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 4 | 1 | Completed 1 |
Follow ART123: new trials by email Literature Review of ART123 trials Research Report on ART123
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients thrombomodulin alfa, Placebo - Chemotherapy-induced Peripheral Neuropathy | Phase 1 | Terminated | Veloxis Pharmaceuticals | 77 | 2022-03-24 | 2024-08-19 |
| A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo thrombomodulin alfa, Placebo - Chemotherapy-induced Peripheral Neuropathy | Phase 2 | Withdrawn | Veloxis Pharmaceuticals | 2021-10-01 | 2022-02-18 | |
| The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy ART-123, Placebo Comparator - Placebo - Sepsis and Coagulopathy | Phase 3 | Withdrawn | Asahi Kasei Pharma America Corporation | 2019-07-01 | 2019-09-13 | |
| Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer ART-123 (3-day ART), ART-123 (1-day ART), Placebo - Postoperative Stage II/III Colon Cancer | Phase 2 | Completed | Asahi Kasei Therapeutics Corporation | 79 | 2016-07-01 | 2024-04-04 |
| Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis ART-123, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Asahi Kasei Therapeutics Corporation | 74 | 2016-05-01 | 2019-01-18 |
| Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy ART-123, Placebo - Severe Sepsis, Coagulopathy | Phase 3 | Completed | Asahi Kasei Pharma America Corporation | 816 | 2012-10-29 | 2020-04-21 |
| Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment ART-123 - Disseminated Intravascular Coagulation | Phase 4 | Completed | Asahi Kasei Therapeutics Corporation | 40 | 2012-10-01 | 2017-02-15 |
| Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation ART-123, placebo - Sepsis, Disseminated Intravascular Coagulation | Phase 2 | Completed | Artisan Pharma, Inc. | 750 | 2007-07-01 | 2011-05-18 |
Sepsis (3) · Disseminated Intravascular Coagulation (2) · Hemostatic Disorders (2) · Idiopathic Pulmonary Fibrosis (1)
Asahi Kasei Therapeutics Corporation (3) · Asahi Kasei Pharma America Corporation (2) · Veloxis Pharmaceuticals (2) · Artisan Pharma, Inc. (1)
Japan (4) · United States (3) · Canada (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Croatia (1) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Hungary (1) · India (1)
David Fineberg, MD (2) · David Fineberg, M.D. (1) · Libbie McKenzie, MD FASN (1)